TP Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- TP Therapeutics's estimated annual revenue is currently $30.8M per year.
- TP Therapeutics received $80.0M in venture funding in October 2018.
- TP Therapeutics's estimated revenue per employee is $296,442
- TP Therapeutics's total funding is $1.2B.
- TP Therapeutics's current valuation is $1.9B. (January 2022)
Employee Data
- TP Therapeutics has 104 Employees.
- TP Therapeutics grew their employee count by -35% last year.
TP Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is TP Therapeutics?
TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. Our lead therapeutic project, TPX-0005, is in clinical development (TRIDENT-1). TP- Turning Point Medicines for Life!
keywords:Biotechnology,Healthcare,Pharmaceuticals
$1.2B
Total Funding
104
Number of Employees
$30.8M
Revenue (est)
-35%
Employee Growth %
$1.9B
Valuation
N/A
Accelerator
TP Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director, Clinical Development | Reveal Email/Phone |
2 | Senior Director, Head Medical Writing | Reveal Email/Phone |
3 | Desktop Support Systems Administrator | Reveal Email/Phone |
4 | Senior Director, Data Management | Reveal Email/Phone |
5 | Senior Talent Acquisition Specialist | Reveal Email/Phone |
6 | Senior Data Manager | Reveal Email/Phone |
7 | Executive Director, Clinical Development | Reveal Email/Phone |
8 | VP Clinical Operations, Oncology | Reveal Email/Phone |
9 | Director, Biology | Reveal Email/Phone |
10 | Sr. Clinical Research Associate | Reveal Email/Phone |
TP Therapeutics News
About TP-03 TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex...
We are initiating coverage of Axsome Therapeutics with a BUY rating, TP of 120 USD. · Our enthusiasm revolves around the April 29th PDUFA for AXS...
... Pipeline of Novel Cancer Therapeutics at AACR Annual Meeting 2022 ... TP-1287 is an investigational oral CDK9 inhibitor that has shown...
After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market. The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.5 million shares of common stock at a price of $45 a sh ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.6M | 104 | 2% | N/A |
#2 | $20.9M | 104 | 16% | N/A |
#3 | $26.7M | 104 | 6% | N/A |
#4 | $27.6M | 104 | 5% | N/A |
#5 | $30.2M | 104 | -8% | N/A |
TP Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-01-10 | $1.4M | Undisclosed | Article | |
| 2016-03-23 | $18.0M | Undisclosed | Article | |
| 2017-05-24 | $45.0M | C | Lilly Asia Ventures | Article |
| 2018-10-22 | $80.0M | Undisclosed | Foresite Capital | Article |